Atara Biotherapeutics Inc.
ATRA | NASDAQ
$8.01
-$0.52 (-6.10%)
At close: Oct 30, 2026, 4:00 PM ET
$8.01
$0.00 (0.00%)
Pre-market:
Nov 2, 2026, 4:27 AM ET
-6.10%
(1D)No price chart data available for 1D timeframe.
Rating
42.8
+2.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #460/1028 (Top 45%)
Key Statistics
Market Data
Market Cap $80.4M
1D Range
7.80 8.28
52W Range
4.18 18.09
Valuation (TTM)
PE -6.79
PB -2.17
EV/EBITDA -5.89
Valuation (NTM)
Forward PE 6.72
Forward PEG 0.05
Price Target $13.00
Cash Flow
FCF Yield -27.2%
SBC Adj. FCF Yield -32.1%
SBC Impact -17.7%
Margins
Gross Margin 91.4%
Operating Margin -229.7%
FCF Margin -353.5%
Growth (CAGR)
Revenue 3Y | 5Y -3.4% |
-3.5%
Dil EPS 3Y | 5Y 139.7% |
55.7%
FCF 3Y | 5Y 79.2% |
44.0%
Returns
ROA -79.4%
ROE 44.7%
ROIC -93.1%
Financial Health
Net Cash
$9.87M
Current Ratio 1.98
Interest Coverage -5.04
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in...
Sector Healthcare
Industry Biotechnology
Employees 10
IPO Date Oct 16, 2014
Website www.atarabio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$13.00
Upside
+62.30%
Buy (1)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ATRA